SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Fundrise Growth Tech Fund LLC operates as a non-diversified, closed-end management investment company. It invests in growing tech companies to help them expand and generate profits. The company was founded on June 7, 2021 and is headquartered in Washington, DC.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

The Fundrise Innovation Fund ($VCX) is seeing intense retail frenzy and extreme volatility, driven by investor scramble for exposure to private AI and space unicorns like Anthropic, OpenAI, and SpaceX. While some traders are riding the momentum and betting on further gains, community sentiment is heavily polarized due to concerns over its massive premium to net asset value, a restricted share lockup preventing easy selling, and comparisons to other vehicles like $ORBS or $DXYZ.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as investors debate the impact of a bipartisan Senate bill aimed at restricting sports betting contracts on prediction market platforms. While some community members view the legislation as a competitive win that reinforces the company's regulatory moat, others remain skeptical, citing continued insider selling and broader sector volatility.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing positive market sentiment driven by the announced departure of a key FDA official, which investors perceive as a catalyst for a more favorable regulatory environment for its gene therapy pipeline. Community members are actively discussing the stock's significant short interest and the anticipation of upcoming clinical data readouts, fueling speculation about potential institutional accumulation and short-term volatility.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is experiencing extreme volatility and intense community debate following a provocative short report from Culper Research that alleges aggressive channel stuffing practices. While management has issued a rebuttal calling the assertions misleading and false, investors remain deeply divided, with many aggressively adding to their positions in anticipation of a rebound while others express frustration over the perceived weakness of the response and the resulting share price pressure.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is experiencing intense volatility and bearish sentiment as investors react to a recent reverse stock split, which has sparked widespread frustration regarding the company's lack of transparent guidance and perceived mismanagement. The community is actively debating whether the split will genuinely improve institutional appeal or if it is merely a precursor to further dilution, with many retail holders expressing skepticism about the company's long-term viability under current leadership.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is experiencing significant momentum and heavy trading volume as investors react to the company's expanding role in NASA's updated Artemis lunar base infrastructure plans and anticipation of upcoming contract awards. The community is actively debating the stock's volatility and growth prospects, with many bulls focusing on the company's long-term potential as a key service provider for sustained lunar operations.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech 100 is drawing significant attention as traders view it as a primary proxy for exposure to major private tech players, particularly SpaceX and Anthropic. The community is actively debating the fund's heavy premium relative to its net asset value, with some retail investors aggressively accumulating shares in anticipation of a potential SpaceX IPO while others caution against the risk of dilution and overvaluation.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is facing heightened investor scrutiny and volatility as community sentiment grapples with aggressive capital expenditure plans, competitive pressures in the AI space, and broader geopolitical tensions impacting the tech sector. While some traders are actively shorting the stock, citing technical weakness compared to other 'Mag 7' peers, others are highlighting the company's long-term potential in AI infrastructure and cloud growth as a reason to buy the dip.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is seeing significant market activity as investors weigh the potential catalyst of a SpaceX IPO against the companys own upcoming BlueBird 7 launch. The community remains heavily divided between long-term holders betting on institutional partnerships and the broader space sector growth, and skeptical traders voicing frustration over launch delays and insider activity.

Satellogic, Inc. operates as a vertically integrated geospatial company. It is creating and continuously enhancing the first scalable, fully automated EO platform with the ability to remap the entire planet at both high-frequency and high-resolution, providing accessible and affordable solutions for customers. The company was founded by Emiliano Kargieman and Gerardo Richarte in July 2010 and is headquartered in Davidson, NC.

Satellogic Inc - Ordinary Shares - Class A

Satellogic is experiencing heightened momentum as investors react to a newly expanded U.S. Naval research deal and a broader speculative rotation into the space supply chain. The community is actively debating the stock's long-term valuation relative to peers, with many focusing on institutional accumulation and upcoming catalyst events in the space sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

New Strong Buy Stocks for March 25th

EQT, BCBP, FIX, PAAS and ADMA have been added to the Zacks Rank #1 (Strong Buy) List on March 25, 2026.

ADMA Biologics (NASDAQ:ADMA) Stock Price Down 8.7% - What's Next?

ADMA Biologics (NASDAQ:ADMA) Shares Down 8.7% - Should You Sell...

<ul class="summary-bullets"><li>Without the sales figure inflation, Culper estimates Adma's revenues declined 3% in 2025 as compared to the 20% growth reported.&nbsp;</li><li>According to Culper, the growth story for the company’s flagship product Asceniv is already over and the shares of the company are now headed lower.</li><li>Culper alleged, based on its research, that the company induced its distributor to stock excess Asceniv by offering rebates and extended payment terms in order to meet order expectations.</li></ul> Shares of Adma Biologics Inc. (ADMA) closed 17% lower on Tuesday after Culper Research said it has taken a short position in the company.Culper alleged in a report that Adma’s reported growth is a “fiction driven more than entirely by a de facto channel stuffing scheme and an undisclosed related party distributor."Without the sales figure inflation, Culper estimates Adma's revenues declined 3% in 2025 as compared to the 20% growth reported.<h2 class="st-heading-2">Asceniv Sales And Demand</h2>According to Culper, the growth story for the company’s flagship product Asceniv is already over and the shares of the company are now headed lower. Asceniv is an FDA-approved intravenous immune globulin used for treating Primary Humoral Immunodeficiency (PI), a common inborn error of immunity characterized by reduced or dysfunctional antibody production.Culper alleged, based on its research, that the company induced its distributor to stock excess Asceniv by offering rebates and extended payment terms in order to meet order expectations. However, there isn’t as much demand, leaving distributors with excess inventory, the firm said.“Distributors take unwanted product without having to pay for it, ADMA books the revenues, and reports growth that was never there,” the firm alleged, while adding that it believes that the company’s reported Asceniv revenues are inflated by 40-76%. Culper also noted that company insiders, including CEO Adam Grossman, have collectively sold over $50 million in stock in the past 3 years.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ADMA stock rose from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/ADMA">ADMA stock</a> has dived 44% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-terafab-project-first-step-towards-tesla-spacex-merger-says-wedbush/cZ3nAP9RI10">Elon Musk’s Terafab Project First Step Towards Tesla-SpaceX Merger, Says Wedbush</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the ADMA Biologics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

ADMA Stock Drops 17% After Culper Research Alleges Channel Stuffing

Culper alleged that Adma’s reported growth is a “fiction driven more than entirely by a de facto channel stuffing scheme and an undisclosed related party distributor." 

Equity

Culper alleged that Adma’s reported growth is a “fiction driven more than entirely by a de facto channel stuffing scheme and an undisclosed related party distributor." 


LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug

Lexicon Pharmaceuticals stock jumps as NVO launches phase I study of oral obesity candidate LX9851, advancing a promising partnered therapy.

APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy

Apogee Therapeutics jumps 20% as 52-week phase II Part A data show sustained efficacy of its AD candidate, zumilokibart, with durable responses and infrequent dosing boosting its promise.

ADMA Biologics (NASDAQ:ADMA) Sets New 52-Week Low  - Here's Why

ADMA Biologics (NASDAQ:ADMA) Hits New 52-Week Low - Should You Sell...

FDA Approves BMY's Opdivo Label Expansion in Classical Hodgkin Lymphoma

Bristol Myers expands Opdivo's reach with new U.S. and EU approvals in Hodgkin lymphoma, strengthening its immunotherapy leadership and growth outlook.

New Strong Buy Stocks for March 23rd

LCUT, EFXT, MGA, ADMA and JLL have been added to the Zacks Rank #1 (Strong Buy) List on March 23, 2026.

Tealwood Asset Management Inc. Takes Position in ADMA Biologics Inc $ADMA

Tealwood Asset Management Inc. purchased a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) during the fourth quarter, according to its most recent filing with the Securities...

Tealwood Asset Management Inc. Invests $1.32 Million in ADMA Biologics Inc $ADMA

Tealwood Asset Management Inc. bought a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the...

Traders are intensely debating the validity of a negative report from Culper Research that accuses the company of channel stuffing.

Investors are expressing growing frustration and demands for management to issue a formal rebuttal against current short-seller allegations.

Many retail traders view the sharp share price decline as a significant opportunity to load up on discounted shares before a rebound.

Bullish investors are speculating that current heavy short interest will trigger a sharp upside move as short-sellers begin covering their positions.

The discussion highlights a divide between those betting on long-term growth and others fearing the stock's recent technical breakdown.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	$0.19	--	--	N/A
Q4 '25	$0.19	$0.21	15.22%	BEAT
Q3 '25	$0.15	$0.16	6.75%	BEAT
Q2 '25	$0.14	$0.15	7.78%	BEAT
Q1 '25	$0.15	$0.14	-11.21%	MISSED

ADMA
Adma Biologics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest ADMA News

ADMAAdma Biologics Inc